Latest
- Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study
- Establishing Medical Intelligence - Leveraging FHIR to Improve Clinical Management: a retrospective cohort and clinical implementation study
- Characteristics and outcomes of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with lutetium-177–PSMA-617 (PSMA-RLT) in a real-world setting.
- Anatomy-Guided Pathology Segmentation
- Decoding pan-cancer treatment outcomes using multimodal real-world data and explainable artificial intelligence
- Intraoperative Molecular Positron Emission Tomography Imaging for Intraoperative Assessment of Radical Prostatectomy Specimens
- Accurate Fine-Grained Segmentation of Human Anatomy in Radiographs via Volumetric Pseudo-Labeling
- Establishing Medical Intelligence - Leveraging FHIR to Improve Clinical Management
- Evaluation of thresholding methods for the quantifcation of 68Ga‑PSMA‑11 PET molecular tumor volume and their efect on survival prediction in patients with advanced prostate cancer undergoing 177Lu‑PSMA‑617 radioligand therapy
- Artificial intelligence guided enhancement of digital PET: scans as fast as CT?
- Virtual Biopsy: Just an AI Software or a Medical Procedure?
- Joint Imaging Platform for Federated Clinical Data Analytics
- PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis
- Semi-automatically quantified tumor volume using Ga-68-PSMA-11-PET as biomarker for survival in patients with advanced prostate cancer
- Analysis of PSMA expression and outcome in patients with advanced Prostate Cancer receiving $^textrm177$ Lu-PSMA-617 Radioligand Therapy